Proof of Biological Activity of SAR100842 in Systemic Sclerosis



Status:Completed
Conditions:Neurology, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery, Neurology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:January 2013
End Date:April 2014

Use our guide to learn which trials are right for you!

Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis

Primary Objective:

- To evaluate safety and tolerability of 8-week oral administration of SAR100842 in patients
with diffuse cutaneous systemic sclerosis.

Secondary Objectives:

- To evaluate the pharmacodynamic effect of SAR100842 in patients with systemic sclerosis
as measured by disease related biomarkers and Lysophosphatidic acid (LPA) receptor
signaling markers in blood and skin;

- To explore the effect of SAR100842 on skin thickness in patients with systemic
sclerosis as measured by the modified Rodnan Skin Score (mRSS);

- To explore the effect of SAR100842 on quality of life as measured by the Scleroderma
Modified Health Assessment Questionnaire (SHAQ);

- To document long term safety of SAR100842 during the extension part.

Core part: randomized, double-blind, placebo-controlled study - 8-week treatment Extension
part for participants completing the core part: Open label non-controlled study - 16-week
treatment

Each patient's participation in the study will be approximately 13 or 33 weeks depending on
their participation in the extension part: up to 2 weeks of screening, 8 weeks of treatment
in the core part, 1 to 30 days wash-out between core part and extension part , 16 weeks of
treatment in the extension part and 3 weeks of follow up.

Inclusion criteria :

- Patients who meet the American College of Rheumatology (ACR) criteria for systemic
sclerosis with diffuse cutaneous involvement and <36 months since the onset of the first
systemic sclerosis manifestation other than Raynaud's phenomenon and have a Modified
Rodnan Skin Score (mRSS) ≥ 15 and an area of definite involvement of the dorsal forearm
that is considered amenable to repeated 4mm skin biopsies.

Exclusion criteria:

1. Patients with high dose or unstable low dose immunosuppressive drugs, cytotoxic,
anti-fibrotic or glucocorticoids drugs at least 4 weeks prior to screening

2. Serum creatinine > 2.0 mg/dL

3. Gastrointestinal involvement preventing oral administration of study drug

4. Severe cardiac and/or pulmonary disease

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.
We found this trial at
8
sites
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Lille,
Click here to add this to my saved trials
New Brunswick, New Jersey 08901
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Washington,
Click here to add this to my saved trials